Kardigan Q2 FY26 net loss widens to $116.24 million; R&D expenses rise to $56.37 million

Reuters2026/08/11 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kardigan posted a Q2 net loss of USD 116.24 million, widening from USD 57.45 million a year earlier.
RD expense climbed to USD 56.37 million from USD 35.84 million, driven by higher clinical-trial spending and headcount growth.
Cash, cash equivalents and investments rose to USD 660.69 million at June 30 from USD 335.49 million at Dec. 31, reflecting IPO proceeds.
GA expense eased to USD 18.87 million from USD 21.29 million, on the absence of a prior-year one-time integration bonus.
Pipeline update: Phase 3 portion of KINSHIP-DCM is underway; Phase 2b topline data for danicamtiv, ataciguat, tonlamarsen targeted in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kardigan Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811514909) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kardigan Q2 FY26 net loss widens to $116.24 million; R&D expenses rise to $56.37 million

You may also like

Crypto prices